BMS-202

BMS-202
臨床資料
ATC碼	未分配;
法律規範狀態
法律規範	Investigational;
識別資訊
	IUPAC命名法 N-(2-(((2-methoxy-6-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)pyridin-3-yl)methyl)amino)ethyl)acetamide; ;
CAS號	1675203-84-5
PubChem CID	117951478;
IUPHAR/BPS	9607;
ChemSpider	45743495;
UNII	KDA2HUE7KP;
ChEMBL	ChEMBL4089730 ;
化學資訊
化學式	C25H29N3O3
摩爾質量	419.53 g·mol−1
3D模型（JSmol）	交互式圖像;
	SMILES CC1=C(C=CC=C1C2=CC=CC=C2)COC3=NC(=C(C=C3)CNCCNC(=O)C)OC;
	InChI InChI=1S/C25H29N3O3/c1-18-22(10-7-11-23(18)20-8-5-4-6-9-20)17-31-24-13-12-21(25(28-24)30-3)16-26-14-15-27-19(2)29/h4-13,26H,14-17H2,1-3H3,(H,27,29); Key:JEDPSOYOYVELLZ-UHFFFAOYSA-N;

參考文獻

^ Cai Y, Xiao M, Li X, Zhou S, Sun Y, Yu W, Zhao T. BMS-202, a PD-1/PD-L1 inhibitor, decelerates the pro‑fibrotic effects of fibroblasts derived from scar tissues via ERK and TGFβ1/Smad signaling pathways. Immunity, Inflammation and Disease. 2022, 10 (10): e693. PMC 9449589 . PMID 36169254. doi:10.1002/iid3.693.
^ Ashizawa T, Iizuka A, Tanaka E, Kondou R, Miyata H, Maeda C, Sugino T, Yamaguchi K, Ando T, Ishikawa Y, Ito M, Akiyama Y. Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse. Biomedical Research. 2019, 40 (6): 243–250. PMID 31839668. doi:10.2220/biomedres.40.243 .